Opendata, web and dolomites

BERMES SIGNED

A Novel BERberine derivative for Malignant MESothelioma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BERMES project word cloud

Explore the words cloud of the BERMES project. It provides you a very rough idea of what is the project "BERMES" about.

therapy    peak    agent    manufacture    orphan    preliminary    gap    none    obtaining    regulatory    improvement    undertaken    banned    malignant    antitumour    incidences    aggressive    44    burden    clinical    agency    death    thin    tissue    designation    pharmacokinetic    internal    mesothelium    combination    first    resistant    safety    survival    valley    innovative    bermes    organs    arising    translational    cisplatin    chemoresistance    world    deal    treatment    layer    derivative    definitely    peritoneal    solved    mesothelioma    completion    standard    covers    berberine    limited    medicine    close    exposure    toxicity    union    pulling    worldwide    administered    authorization    good    lungs    rare    health    nax035    disease    cavity    period    organization    right    drug    shown    testis    malignancy    forms    latency    line    emergence    heart    last    data    oral    diagnosis    mm    drugs    2005    january    asbestos    trial    despite    efficacy    2020    exhibited    trials    pemetrexed   

Project "BERMES" data sheet

The following table provides information about the project.

Coordinator
APPLIED RESEARCH USING OMIC SCIENCES SL 

Organization address
address: CALLE VICTOR PRADERA 45
city: CORNELLA
postcode: 8940
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙550˙942 €
 EC max contribution 1˙085˙659 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    APPLIED RESEARCH USING OMIC SCIENCES SL ES (CORNELLA) coordinator 1˙085˙659.00

Map

 Project objective

Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis. The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020. The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance. NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BERMES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BERMES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More